Over the past decade there has been increasing research and clinical interest in the role of exercise therapy/rehabilitation as an adjunct therapy to improve symptom control and management following a cancer diagnosis. More recently, the field of 'exercise -oncology' has broadened in scope to investigate whether the benefits extend beyond symptom control to modulate cancer-specific outcomes (i.e., cancer progression and metastasis). Here we review the extant epidemiological evidence examining the association between exercise behavior, functional capacity/exercise capacity, and cancer-specific recurrence and mortality as well as all-cause mortality individuals following a cancer diagnosis. We also evaluate evidence from clinical studies investigating the effects of structured exercise on blood-based biomarkers associated with cancer progression/metastasis as well findings from preclinical investigations examining the effects and molecular mechanisms of exercise in mouse models of cancer. Current gaps in knowledge are also discussed.
Introduction
The health benefits of regular exercise have been recognized for centuries. Indeed, structured exercise training is established as the cornerstone of primary and secondary disease prevention in multiple clinical settings. In contrast, it has not been until the past decade or so that exercise has gained acceptance as a potential adjunct therapy following a cancer diagnosis (Jones and Demark-Wahnefried, 2006; Jones et al., 2010a) . To date, approximately, 80 studies have been conducted investigating the effects of structured exercise training in patients following a diagnosis of cancer. Meta-analyses and systematic reviews report that structured exercise training is a safe and well-tolerated therapeutic strategy associated with significant improvements in a broad range of cancer-related toxicities including fatigue, exercise capacity, and physical quality of life (Jones et al., 2011; McNeely et al., 2006; Speck et al., 2010) . Based on the extant literature, several national and international organizations have published exercise guidelines for cancer patients both during and following the completion of adjuvant therapy (Hayes et al., 2009; Schmitz et al., 2010) .
While the importance of exercise therapy to control and/or mitigate the adverse consequences of cancer therapy are undisputed, there is growing interest in determining whether the benefits extend beyond symptom control to modulate cancer-specific outcomes (i.e., cancer progression and metastasis). Elucidation of the effects and underlying mechanisms will be critical to inform hypothesis-driven clinical trials and ensure the optimal safety and efficacy of exercise in cancer control. Accordingly, over the past several years, exercise-oncology researchers from a wide variety of disciplines have started to investigate the association between exercise behavior, objective measures of exercise capacity/ functional capacity, and prognosis following a cancer diagnosis as well as the cellular and molecular mechanisms underlying these associations. The purpose of this paper is to review: (1) the extant epidemiological evidence examining the association between exercise behavior, functional capacity/exercise capacity, and cancerspecific recurrence and mortality as well as all-cause mortality, and (2) studies elucidating the host and cellular mechanisms underlying the exercise-prognosis relationship. In terms of the latter, we evaluate evidence from clinical studies investigating the effects of structured exercise training ('structured' exercise is defined as studies testing a specific plan of physical activity designed to improve exercise capacity as opposed to studies designed to increase physical activity) on changes in blood-based biomarkers proposed to mediate the association between exercise behavior/exercise capacity and cancer-specific prognosis.
Further, we also review the evidence from preclinical investigations examining the effects of exercise on tumor progression and metastasis in mouse models of cancer.
Search strategy
A comprehensive literature review using PubMed, MEDLINE, Sport Discus, and Cochrane Controlled Trials Register (1966 
